Lanadelumab

證據等級: L5

預測適應症: 10 個

Lanadelumab: From Hereditary Angioedema to C1 Inhibitor Deficiency

One-Sentence Summary

Lanadelumab (Takhzyro) is a fully human monoclonal antibody globally approved since 2018 for preventing acute attacks of Hereditary Angioedema (HAE) due to C1 inhibitor deficiency, but not yet registered in Italy. The TxGNN model predicts it highly effective for C1 Inhibitor Deficiency (HAE Type I/II) in the Italian market, backed by 22 clinical trials and 20 publications. This represents one of the strongest evidence bases encountered in rare disease drug evaluation, with multiple completed Phase 3 RCTs and a pivotal publication in JAMA confirming efficacy.

Quick Overview

Item	Content
Original Indication	HAE Type I/II attack prevention (globally approved; no Italian registration found)
Predicted New Indication	C1 Inhibitor Deficiency
TxGNN Prediction Score	99.9955%
Evidence Level	L1
Italy Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Lanadelumab is a fully human IgG1 monoclonal antibody that selectively inhibits plasma kallikrein (pKal), a serine protease at the centre of the contact activation pathway. In patients with HAE Type I or II, mutations in the SERPING1 gene lead to deficiency or dysfunction of C1 inhibitor (C1-INH). C1-INH is the principal brake on the contact activation cascade — without it, pKal activity runs unchecked, cleaving high-molecular-weight kininogen (HMWK) to release excessive bradykinin. Bradykinin then acts on B2 receptors to cause fluid extravasation into subcutaneous and submucosal tissues, producing the painful, potentially life-threatening swelling episodes that define HAE. By directly blocking pKal upstream, lanadelumab prevents bradykinin overproduction before an attack begins, rather than treating it after the fact.

C1 inhibitor deficiency is not merely related to HAE Type I/II — it is its biochemical definition. The predicted indication and the drug's established mechanism are therefore a direct one-to-one match. The pivotal HELP Phase 3 RCT (NCT02586805, published in JAMA 2018) demonstrated statistically significant and clinically meaningful reductions in attack frequency versus placebo, leading to FDA approval in August 2018 and EMA approval shortly thereafter. Phase 3 studies across Japanese, Chinese, and paediatric populations have since replicated these findings, while multiple large real-world programmes (ENABLE, EMPOWER, INTEGRATED) confirm sustained effectiveness in routine clinical practice.

The TxGNN model's near-perfect prediction score (>99.99%) reflects the strength of this mechanistic and clinical relationship within the drug–disease knowledge graph. This is not a novel repurposing hypothesis requiring speculative extrapolation — it is a strong computational confirmation of an established clinical reality that Italy has yet to formally register.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02586805	Phase 3	Completed	125	HELP Study — Pivotal Phase 3 double-blind RCT of DX-2930 (lanadelumab) vs placebo in HAE Type I/II. Demonstrated significant reduction in acute angioedema attack rate; primary basis for FDA and EMA regulatory approval.
NCT02741596	Phase 3	Completed	212	HELP OLE — Long-term open-label extension; evaluated sustained safety and efficacy of lanadelumab over an extended treatment period (>4 years) in HAE Type I/II.
NCT04070326	Phase 3	Completed	21	SPRING Study — Paediatric Phase 3 trial in children aged 2–<12 years; assessed pharmacokinetics, pharmacodynamics, safety, and reduction in HAE attack frequency.
NCT05460325	Phase 3	Completed	20	Multicenter open-label study in Chinese patients with HAE; evaluated safety profile and pharmacokinetics over 26 weeks.
NCT04180163	Phase 3	Completed	12	Japanese Phase 3 study; confirmed safety and efficacy of lanadelumab in Japanese HAE Type I/II patients.
NCT04444895	Phase 3	Completed	73	Long-term open-label study in non-histaminergic angioedema with normal C1-INH; explored lanadelumab efficacy beyond classical HAE Type I/II.
NCT04130191	N/A	Completed	140	ENABLE Study — 3-year prospective real-world observational study comparing HAE attack rates before and after lanadelumab initiation in routine clinical practice across multiple countries.
NCT03845400	N/A	Completed	168	EMPOWER Study — US and Canada real-world cohort; compared HAE attack frequency pre- and post-lanadelumab initiation over ≥24 months, with data collected via smartphone application.
NCT05147181	N/A	Completed	48	Polish National Drug Program observational study; documented proportion of attack-free patients, attack characteristics, and rescue treatment use in real-life HAE care.
NCT04861090	N/A	Completed	207	Retrospective multicountry chart review; assessed real-world attack-free rates with lanadelumab dosed every 2 weeks and every 4 weeks.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30480729	2018	RCT	JAMA	HELP trial primary results: lanadelumab significantly reduced HAE attack rate vs placebo across all dose regimens; the landmark publication underpinning global regulatory approval.
34287942	2022	Extension Study	Allergy	HELP OLE: sustained reduction in HAE attacks confirmed over ≥4 years of treatment; durable efficacy and acceptable long-term safety profile.
39701274	2025	Real-World Study	J Allergy Clin Immunol Pract	INTEGRATED multicountry observational study: real-world effectiveness of lanadelumab across multiple countries confirms phase 3 findings in everyday clinical practice.
40434599	2025	Network Meta-Analysis	Drugs R&D	Network meta-analysis comparing lanadelumab, garadacimab, SC C1-INH, and berotralstat for HAE long-term prophylaxis; provides indirect head-to-head comparative efficacy and safety data.
39508959	2024	Systematic Review	Clin Rev Allergy Immunol	Systematic review of breakthrough HAE attacks during long-term prophylaxis; characterises attack burden in patients on lanadelumab and other agents.
32187470	2020	Review	N Engl J Med	Comprehensive NEJM review of hereditary angioedema: pathophysiology, diagnostic criteria, and current treatment landscape including lanadelumab.
30267321	2018	Approval Review	Drugs	First Global Approval summary: mechanism of action, PK/PD profile, clinical trial results, and regulatory milestones for lanadelumab (Takhzyro).
30539362	2019	Review	BioDrugs	Detailed review of preclinical and Phase I data supporting lanadelumab's mechanism validation, pharmacokinetics, and early clinical safety in C1-INH-HAE.
39836016	2025	Indirect Comparison	J Comp Effectiveness Res	Indirect treatment comparison of lanadelumab vs C1-esterase inhibitor in paediatric HAE (aged <12 years); supports lanadelumab's relative efficacy and safety in children.
37328263	2023	Real-World Study	Allergy Asthma Proc	Healthcare resource utilisation in new users of lanadelumab vs subcutaneous C1-INH in US real-world setting; includes demographics, cost data, and clinical outcomes.

Italy Market Information

No authorizations for lanadelumab are currently registered in Italy (0 AIFA licenses). Lanadelumab is globally marketed as Takhzyro (Takeda, formerly Shire), with centralised EMA approval since 2018 and FDA approval since August 2018, for prophylaxis of HAE attacks in patients aged ≥12 years. Approval has since been extended to children aged 2–<12 years in some jurisdictions. A formal regulatory submission to AIFA would be required for Italian market entry, though the EMA approval pathway may facilitate an expedited process.

Safety Considerations

Please refer to the Takhzyro European Summary of Product Characteristics (SmPC) for complete safety information. Detailed Italian-specific safety data (AIFA package insert warnings, contraindications, and drug-drug interactions) could not be retrieved, as lanadelumab is not currently registered in Italy and no DDI data were identified in the available databases.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Lanadelumab has robust L1-level evidence for C1 inhibitor deficiency (HAE Type I/II), anchored by multiple completed Phase 3 RCTs — including the pivotal JAMA-published HELP trial — and reinforced by large real-world programmes across the US, Europe, Japan, and China. The TxGNN prediction score of >99.99% is a computational confirmation of a well-established clinical indication, not a speculative hypothesis. The sole barrier to use in Italy is regulatory registration, not evidence.

To proceed, the following is needed:

Initiate AIFA regulatory review using the EMA centralised approval package (Takhzyro SmPC), leveraging the mutual recognition / decentralised procedure pathway
Obtain and review the full EMA SmPC for complete contraindications, warnings, and drug-drug interaction data before clinical use
Assess reimbursement eligibility for HAE Type I/II under the Italian NHS (SSN), including potential bridging access via Law 648/96 while formal approval is pending
Identify accredited HAE specialist and angioedema reference centres in Italy to ensure appropriate patient selection, monitoring, and pharmacovigilance reporting
Develop a risk management plan (RMP) consistent with EMA PASS requirements, particularly for paediatric and high-risk populations (e.g. renal transplant patients, as highlighted in recent literature)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.